125 related articles for article (PubMed ID: 26080469)
1. Authors' response.
Ramzi N; Chahil J; Lye S; Metnam K; Sahadevappa K; Velapasamy S; Hashim N; Cheah S; Lim G; Hussein H; Haron M; Alex L; Ler LW
Indian J Med Res; 2015 Feb; 141(2):246. PubMed ID: 26080469
[No Abstract] [Full Text] [Related]
2. Matching for risk factors in case control studies.
Kaushal K
Indian J Med Res; 2015 Feb; 141(2):245. PubMed ID: 25900963
[No Abstract] [Full Text] [Related]
3. Association of CYP2C9 genotypes leading to high enzyme activity and colorectal cancer risk.
Yasar U; Eliasson E; Dahl ML
Carcinogenesis; 2002 Apr; 23(4):665; author reply 667-8. PubMed ID: 11960920
[No Abstract] [Full Text] [Related]
4. Detection of cytochrome P450 1B1 Bfr I polymorphism: genotype distribution in healthy German individuals and in patients with colorectal carcinoma.
Fritsche E; Brüning T; Jonkmanns C; Ko Y; Bolt HM; Abel J
Pharmacogenetics; 1999 Jun; 9(3):405-8. PubMed ID: 10471075
[No Abstract] [Full Text] [Related]
5. Genotyping of CYP3A5 polymorphisms among Bulgarian patients with sporadic colorectal cancer and controls.
Petrova DT; Yaramov N; Toshev S; Nedeva P; Maslyankov S; von Ahsen N; Oellerich M; Toncheva D
Onkologie; 2007 Nov; 30(11):559-63. PubMed ID: 17992026
[TBL] [Abstract][Full Text] [Related]
6. Prostacyclin synthase and arachidonate 5-lipoxygenase polymorphisms and risk of colorectal polyps.
Poole EM; Bigler J; Whitton J; Sibert JG; Potter JD; Ulrich CM
Cancer Epidemiol Biomarkers Prev; 2006 Mar; 15(3):502-8. PubMed ID: 16537708
[TBL] [Abstract][Full Text] [Related]
7. Cooking methods, metabolic polymorphisms and colorectal cancer.
Pisani P; Mitton N
Eur J Cancer Prev; 2002 Feb; 11(1):75-84. PubMed ID: 11917213
[No Abstract] [Full Text] [Related]
8. A pharmacogenetic study to investigate the role of dietary carcinogens in the etiology of colorectal cancer.
Sachse C; Smith G; Wilkie MJ; Barrett JH; Waxman R; Sullivan F; Forman D; Bishop DT; Wolf CR;
Carcinogenesis; 2002 Nov; 23(11):1839-49. PubMed ID: 12419832
[TBL] [Abstract][Full Text] [Related]
9. Genetic polymorphisms in cytochrome P450 and clinical outcomes of FOLFIRI chemotherapy in patients with metastatic colorectal cancer.
Dong N; Meng F; Wu Y; Wang M; Cui Y; Zhang S
Tumour Biol; 2015 Sep; 36(10):7691-8. PubMed ID: 25934339
[TBL] [Abstract][Full Text] [Related]
10. Association of CYP2C9 genotypes leading to high enzyme activity and colorectal cancer risk.
Martínez C; García-Martín E; Ladero JM; Sastre J; Garcia-Gamito F; Diaz-Rubio M; Agúndez JA
Carcinogenesis; 2001 Aug; 22(8):1323-6. PubMed ID: 11470765
[TBL] [Abstract][Full Text] [Related]
11. CYP1B1, but not CYP1A1, is downregulated by promoter methylation in colorectal cancers.
Habano W; Gamo T; Sugai T; Otsuka K; Wakabayashi G; Ozawa S
Int J Oncol; 2009 Apr; 34(4):1085-91. PubMed ID: 19287966
[TBL] [Abstract][Full Text] [Related]
12. CYP3A4/5 and pharmacogenetics in patients with sarcoma - Authors' reply.
Wunder JS; Nielsen TO; Maki RG; O'sullivan B; Alman BA
Lancet Oncol; 2007 Aug; 8(8):668-9. PubMed ID: 17679079
[No Abstract] [Full Text] [Related]
13. Combinations of cytochrome P450 gene polymorphisms enhancing the risk for sporadic colorectal cancer related to red meat consumption.
Küry S; Buecher B; Robiou-du-Pont S; Scoul C; Sébille V; Colman H; Le Houérou C; Le Neel T; Bourdon J; Faroux R; Ollivry J; Lafraise B; Chupin LD; Bézieau S
Cancer Epidemiol Biomarkers Prev; 2007 Jul; 16(7):1460-7. PubMed ID: 17627011
[TBL] [Abstract][Full Text] [Related]
14. Cytochrome p450 profile of colorectal cancer: identification of markers of prognosis.
Kumarakulasingham M; Rooney PH; Dundas SR; Telfer C; Melvin WT; Curran S; Murray GI
Clin Cancer Res; 2005 May; 11(10):3758-65. PubMed ID: 15897573
[TBL] [Abstract][Full Text] [Related]
15. Association between exposure-relevant polymorphisms in CYP1B1, EPHX1, NQO1, GSTM1, GSTP1 and GSTT1 and risk of colorectal cancer in a Czech population.
Hlavata I; Vrana D; Smerhovsky Z; Pardini B; Naccarati A; Vodicka P; Novotny J; Mohelnikova-Duchonova B; Soucek P
Oncol Rep; 2010 Nov; 24(5):1347-53. PubMed ID: 20878130
[TBL] [Abstract][Full Text] [Related]
16. Genetic variability in CYP3A4 and CYP3A5 in primary liver, gastric and colorectal cancer patients.
Gervasini G; García-Martín E; Ladero JM; Pizarro R; Sastre J; Martínez C; García M; Diaz-Rubio M; Agúndez JA
BMC Cancer; 2007 Jul; 7():118. PubMed ID: 17605821
[TBL] [Abstract][Full Text] [Related]
17. Association between allelic polymorphisms of metabolizing enzymes (CYP 1A1, CYP 1A2, CYP 2E1, mEH) and occurrence of colorectal cancer in Hungary.
Kiss I; Orsós Z; Gombos K; Bogner B; Csejtei A; Tibold A; Varga Z; Pázsit E; Magda I; Zölyomi A; Ember I
Anticancer Res; 2007; 27(4C):2931-7. PubMed ID: 17695473
[TBL] [Abstract][Full Text] [Related]
18. CYP1A1 genetic polymorphisms and in situ colorectal cancer.
Sivaraman L; Leatham MP; Yee J; Wilkens LR; Lau AF; Le Marchand L
Cancer Res; 1994 Jul; 54(14):3692-5. PubMed ID: 7913406
[TBL] [Abstract][Full Text] [Related]
19. Expression of paclitaxel-inactivating CYP3A activity in human colorectal cancer: implications for drug therapy.
Martínez C; García-Martín E; Pizarro RM; García-Gamito FJ; Agúndez JA
Br J Cancer; 2002 Sep; 87(6):681-6. PubMed ID: 12237780
[TBL] [Abstract][Full Text] [Related]
20. Polymorphisms in the cytochrome P450 genes CYP1A2, CYP1B1, CYP3A4, CYP3A5, CYP11A1, CYP17A1, CYP19A1 and colorectal cancer risk.
Bethke L; Webb E; Sellick G; Rudd M; Penegar S; Withey L; Qureshi M; Houlston R
BMC Cancer; 2007 Jul; 7():123. PubMed ID: 17615053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
